User profiles for Frank DeFalco

Frank J DeFalco

Janssen Research & Development
Verified email at its.jnj.com
Cited by 1505

Characterizing treatment pathways at scale using the OHDSI network

…, MJ Schuemie, FJ DeFalco… - Proceedings of the …, 2016 - National Acad Sciences
Observational research promises to complement experimental research by providing large,
diverse populations that would be infeasible for an experiment. Observational research can …

Feasibility and utility of applications of the common data model to multiple, disparate observational health databases

…, Q Ma, C Knoll, M Schuemie, FJ DeFalco… - Journal of the …, 2015 - academic.oup.com
Objectives To evaluate the utility of applying the Observational Medical Outcomes Partnership
(OMOP) Common Data Model (CDM) across multiple observational databases within an …

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with …

…, JB Buse, MJ Schuemie, F DeFalco… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims Sodium glucose co‐transporter 2 inhibitors (SGLT2i) are indicated for treatment of type
2 diabetes mellitus (T2DM); some SGLT2i have reported cardiovascular benefit, and some …

Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: a retrospective cohort …

Z Yuan, FJ DeFalco, PB Ryan… - Diabetes, Obesity …, 2018 - Wiley Online Library
Aims To examine the incidence of amputation in patients with type 2 diabetes mellitus (T2DM)
treated with sodium glucose co‐transporter 2 (SGLT2) inhibitors overall, and canagliflozin …

Increasing trust in real-world evidence through evaluation of observational data quality

C Blacketer, FJ Defalco, PB Ryan… - Journal of the …, 2021 - academic.oup.com
Objective Advances in standardization of observational healthcare data have enabled
methodological breakthroughs, rapid global collaboration, and generation of real-world evidence …

[HTML][HTML] Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study

…, J Cho, AC Culhane, A Davydov, FJ DeFalco… - Nature …, 2020 - nature.com
Comorbid conditions appear to be common among individuals hospitalised with coronavirus
disease 2019 (COVID-19) but estimates of prevalence vary and little is known about the …

[HTML][HTML] Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents

Y Wang, M Desai, PB Ryan, FJ DeFalco… - Diabetes research and …, 2017 - Elsevier
Aims To estimate and compare incidence of diabetes ketoacidosis (DKA) among patients
with type 2 diabetes who are newly treated with SGLT2 inhibitors (SGLT2i) versus non-SGLT2i …

[HTML][HTML] Multisite evaluation of a data quality tool for patient-level clinical data sets

V Huser, FJ DeFalco, M Schuemie, PB Ryan, N Shang… - EGEMs, 2016 - ncbi.nlm.nih.gov
Methods: We describe a data quality analysis tool (called Achilles Heel) developed by the
Observational Health Data Sciences and Informatics Collaborative (OHDSI) and compare …

Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational …

…, J Weaver, L Hester, Z Yuan, F DeFalco… - … and drug safety, 2019 - Wiley Online Library
Purpose To compare the incidence of diabetic ketoacidosis (DKA) among patients with type
2 diabetes mellitus (T2DM) who were new users of sodium glucose co‐transporter 2 …

Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS

…, E Burn, E Roel, EH Tan, E Minty, F DeFalco… - Clinical …, 2022 - Taylor & Francis
Purpose Routinely collected real world data (RWD) have great utility in aiding the novel
coronavirus disease (COVID-19) pandemic response. Here we present the international …